Literature DB >> 24922689

Utility of measuring circulating tumor cell counts to assess the efficacy of treatment for carcinomas of unknown primary origin.

Keigo Komine1, Masahiro Inoue1, Kazunori Otsuka1, Koji Fukuda1, Hiroshi Nanjo2, Hiroyuki Shibata3.   

Abstract

BACKGROUND/AIM: Carcinomas of unknown primary origin (CUPs) account for 3%-5% of all malignancies. The majority of CUPs have unfavorable prognosis and are chemoresistant. Predictive biomarkers should be established to improve therapeutic outcomes. Metastatic ability of CUPs may be related to the existence of circulating tumor cells (CTCs). PATIENTS AND METHODS: Ten patients diagnosed with CUP visiting the Akita University Hospital participated in this study. CTCs were calculated by the CellSearch system.
RESULTS: The present observational study indicates that CTCs were detected in 50% of CUPs, and in 80% chemotherapeutically-naïve cases. Furthermore, decrease in CTC count between the pre-treatment and post-treatment phases were observed in chemosensitive cases.
CONCLUSION: Rapid assessment of the efficacy of chemotherapy by CTC count may become a useful predictive biomarker of CUPs. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Biomarker; carcinomas of unknown primary origin; chemotherapy; circulating tumor cell; prediction

Mesh:

Substances:

Year:  2014        PMID: 24922689

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

Review 1.  Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.

Authors:  Sebastián Moran; Anna Martinez-Cardús; Stergios Boussios; Manel Esteller
Journal:  Nat Rev Clin Oncol       Date:  2017-07-04       Impact factor: 66.675

2.  Circulating tumor cell count as a biomarker of a specific gastric cancer subgroup characterized by bone metastasis and/or disseminated intravascular coagulation - an early indicator of chemotherapeutic response.

Authors:  Masahiro Inoue; Kazunori Otsuka; Hiroyuki Shibata
Journal:  Oncol Lett       Date:  2015-12-24       Impact factor: 2.967

3.  The biology and clinical potential of circulating tumor cells.

Authors:  Taja Lozar; Klara Gersak; Maja Cemazar; Cvetka Grasic Kuhar; Tanja Jesenko
Journal:  Radiol Oncol       Date:  2019-05-08       Impact factor: 2.991

Review 4.  Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'.

Authors:  Alicia-Marie Conway; Claire Mitchell; Elaine Kilgour; Gerard Brady; Caroline Dive; Natalie Cook
Journal:  Br J Cancer       Date:  2018-12-23       Impact factor: 7.640

Review 5.  Cancer of Unknown Primary: Challenges and Progress in Clinical Management.

Authors:  Noemi Laprovitera; Mattia Riefolo; Elisa Ambrosini; Christiane Klec; Martin Pichler; Manuela Ferracin
Journal:  Cancers (Basel)       Date:  2021-01-25       Impact factor: 6.639

6.  Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches.

Authors:  Noemi Laprovitera; Irene Salamon; Francesco Gelsomino; Elisa Porcellini; Mattia Riefolo; Marianna Garonzi; Paola Tononi; Sabrina Valente; Silvia Sabbioni; Francesca Fontana; Nicolò Manaresi; Antonia D'Errico; Maria A Pantaleo; Andrea Ardizzoni; Manuela Ferracin
Journal:  Front Cell Dev Biol       Date:  2021-06-10

Review 7.  Current Understanding of Circulating Tumor Cells - Potential Value in Malignancies of the Central Nervous System.

Authors:  Lukasz A Adamczyk; Hannah Williams; Aleksandra Frankow; Hayley Patricia Ellis; Harry R Haynes; Claire Perks; Jeff M P Holly; Kathreena M Kurian
Journal:  Front Neurol       Date:  2015-08-10       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.